In this ninth and final installment, Hakan Kaya, MD, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, and Lisa Raff, PharmD, MSPharm, BCPS, BCOP, discuss why hospital partnerships are critical to the successful implementation of bispecific agents into regular multiple myeloma treatment practice.